\n
<\/p>\n
AUSTIN, Texas\u2014Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:), recently sold a significant portion of his holdings in the company. The sale comes as Natera’s stock has shown remarkable strength, with a 159% return over the past year and the company achieving a market capitalization of $22.12 billion. According to a filing with the Securities and Exchange Commission, Moshkevich sold a total of 24,861 shares of Natera’s common stock on January 22, 2025, generating approximately $4.1 million. These transactions occurred at prices ranging from $164.95 to $171.95 per share.<\/p>\n
Following these sales, Moshkevich retains ownership of 140,684 shares in the company. According to the filing, the sales were conducted to satisfy tax withholding obligations related to the vesting of restricted stock units, in accordance with a pre-established trading plan. InvestingPro<\/a> analysis shows Natera maintains a strong financial position with a ‘GOOD’ health score and robust liquidity, as evidenced by a current ratio of 4.39. For deeper insights into insider trading patterns and comprehensive financial analysis, investors can access the detailed Pro Research Report, available exclusively on InvestingPro.<\/p>\n In other recent news, Natera Inc <\/span><\/span> <\/span><\/span>. has been making waves in the industry. Barclays <\/span><\/span> <\/span><\/span> (LON:) recently upgraded the company’s stock rating to Overweight with a $200 target, citing its expansion into new markets and impressive revenue growth of nearly 55% over the last twelve months. Analyst Luke Sergott highlighted Natera’s evolution from its original non-NGS-based NIPT focus to becoming a leading player in the NIPT market and its extension into NGS-based Oncology and Organ Health testing.<\/p>\n Natera has also expanded its patent infringement litigation against NeoGenomics (NASDAQ:) involving the RaDaR assay. Despite facing a setback in a false advertising lawsuit against Guardant Health <\/span><\/span> <\/span><\/span> (NASDAQ:), Natera plans to request the court to overturn the ruling. Additionally, an agreement with Dr. Rabinowitz, the Executive Chairman, has been amended for him to continue his role under certain conditions.<\/p>\n TD (TSX:) Cowen has reiterated a Buy rating on Natera shares, raising the price target from $175 to $195, reflecting confidence in the company’s future performance. Similarly, Baird and Jefferies also maintained favorable ratings on Natera’s stock and raised their price targets. <\/p>\n Lastly, Natera reported a record Q3 revenue of $439.8 million, marking a 64% increase from the previous year, and conducted 137,000 oncology tests. These recent developments provide investors with an insight into Natera’s current status and future prospects.<\/p>\n This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.<\/em><\/p>\n<\/div>\n